Fig. 2From: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trialsEffect of GLP-1 versus placebo on death from cardiovascular causesBack to article page